Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.

Naryan RustgiAnn MariaNicolas ToumbacarisHuiYong ZhaoKatherine KargusMorgan BryantAlexandra WaksmundzkiIlinca AricescuRobert A LefkowitzBob T LiJoanne ChouMarinela CapanuElisa de StanchinaSandra MisaleJinru Shia Rona Yaeger

Published in: The oncologist (2023)

Combined RAF and MEK inhibition does not sufficiently inhibit activated non-V600 BRAF-mutant tumors in patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
wild type
chronic kidney disease
prognostic factors
pi k akt
peritoneal dialysis
metastatic colorectal cancer
young adults